Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C
| العنوان: | Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C |
|---|---|
| المؤلفون: | Andrew Ustianowski, Nikos Kotsopoulos, Mark P. Connolly |
| المصدر: | Journal of Medical Economics, 21(1), 19-26. Taylor & Francis Ltd |
| بيانات النشر: | Taylor & Francis Ltd, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Complementary Therapies, Male, economic evaluation, ledipasvir, IMPACT, Cost-Benefit Analysis, Severity of Illness Index, Cohort Studies, Indirect costs, Tax revenue, 0302 clinical medicine, Cost of Illness, Health care, 030212 general & internal medicine, Prospective Studies, PERSPECTIVE, health care economics and organizations, Cost–benefit analysis, Public economics, Health Policy, Societal impact of nanotechnology, Hepatitis C, Health Care Costs, societal impact, Middle Aged, WORK PRODUCTIVITY, Models, Economic, Social protection, indirect cost, 030211 gastroenterology & hepatology, Female, Uridine Monophosphate, RIBAVIRIN, Adult, INTERFERON, VIRUS-INFECTION, sofosbuvir, public economic, 03 medical and health sciences, medicine, Humans, Fluorenes, business.industry, fiscal, GENOTYPE 1 INFECTION, Hepatitis C, Chronic, medicine.disease, United Kingdom, Early Diagnosis, Economic evaluation, HEALTH-CARE, Benzimidazoles, business |
| الوصف: | Background: Hepatitis C (HCV) infection causes substantial direct health costs, but also impacts broader societal and governmental costs, such as tax revenue and social protection benefits. This study investigated the broader fiscal costs and benefits of curative interventions for chronic Hepatitis C (CHC) that allow individuals to avoid long-term HCV attributed health conditions.Methods: A prospective cohort model, assessing the long-term fiscal consequences of policy decisions, was developed for HCV infected individuals, following the generational accounting analytic framework that combines age-specific lifetime gross taxes paid and governmental transfers received (i.e. healthcare and social support costs). The analysis assessed the burden of a theoretical cohort of untreated HCV infected patients with the alternative of treating these patients with a highly efficacious curative intervention (ledipasvir/sofosbuvir [LDV/SOF]). It also compared treating patients at all fibrosis stages (Stages F0-F4) compared to late treatment (Stage F4).Results: Based on projected lifetime work activity and taxes paid, the treated cohort paid an additional 5,900 pound per patient compared to the untreated cohort. Lifetime government disability costs of 97,555 pound and 125,359 pound per patient for treated cohort vs no treatment cohort were estimated, respectively. Lifetime direct healthcare costs in the treated cohort were 32,235 pound, compared to non-treated cohort of 26,424 pound, with an incremental healthcare costs increase of 5,901 pound per patient. The benefit cost ratio (BCR) of total government benefits and savings relative to government treatment costs (including LDV/SOF) ranged from 1.8-5.6. Treating patients early resulted in 77% less disability costs, 43% lower healthcare costs, and 33% higher tax revenue.Conclusion: The ability to cure Hepatitis C offers considerable fiscal benefits beyond direct medical costs and savings attributed to reduced disability costs, public allowances, and improved tax revenue. Changes in parameters, such as productivity, wage growth, and tax rates, can influence the conclusions described here. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1941-837X 1369-698X 1369-6998 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617b8fd0d17129a7dcf08a84bda04d4bTest https://doi.org/10.1080/13696998.2017.1371032Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....617b8fd0d17129a7dcf08a84bda04d4b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1941837X 1369698X 13696998 |
|---|